In essential thrombocythemia, the bone marrow makes too many platelets (blood-clotting cells). In polycythemia vera, the body makes too many red blood cells. Myelofibrosis is a disorder of the bone marrow in which the marrow is replaced by scar (fibrous) tissue. Myelofibrosis can develop after essential thrombocythemia or polycythemia vera, or on its own (“primary myelofibrosis”).
The purpose of this study is to assess the safety and effectiveness of an investigational drug called AUY922 in patients with primary myelofibrosis or myelofibrosis that has developed after thrombocythemia or polycythemia vera, and which is not responding to standard therapies. AUY922 works by inhibiting a protein called HSP90, which plays a central role in myelofibrosis. It is given intravenously (by vein).